GAM
ALNY icon

Generali Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Generali Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$542K Sell
1,799
-1,394
-44% -$420K 0.01% 400
2026
Q1 		$1.06M Buy
3,193
+3,143
+6,286% +$1.07M 0.02% 383
2025
Q4 		$19.9K Sell
50
-3,184
-98% -$1.41M ﹤0.01% 467
2025
Q3 		$1.47M Buy
3,234
+3,184
+6,368% +$1.3M 0.03% 360
2025
Q2 		$16.3K Hold
50
– – ﹤0.01% 487
2025
Q1 		$13.5K Sell
50
-3
-6% -$771 ﹤0.01% 483
2024
Q4 		$12.5K Buy
+53
New +$13.9K ﹤0.01% 469

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Generali Asset Management's ALNY Position: Q2 2026 in Review

Generali Asset Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 44% in Q2 2026, selling an estimated $420K and leaving 1,799 shares worth $542K. The position accounts for 0.01% of the portfolio, ranked #400.

Generali Asset Management first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.47M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Generali Asset Management held 1,799 shares of Alnylam Pharmaceuticals worth $542K as of Q2 2026.
  • Generali Asset Management sold 1,394 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $420K.
  • Alnylam Pharmaceuticals made up 0.01% of Generali Asset Management's portfolio in Q2 2026, its #400 holding.
  • Generali Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Generali Asset Management's Alnylam Pharmaceuticals position peaked at $1.47M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Generali Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.